A new research report published today, on National Opioid and Substance Awareness Day, by the Employee Benefit Research Institute (EBRI) finds that states’ efforts to increase drug testing of chronic pain patients undergoing long-term opioid therapy have been successful at increasing testing rates. In general, increased testing is important to prevent opioid abuse and help pain patients and their physicians safely manage their conditions.
As of 2023, 24 states have passed laws that require physicians to perform urine drug testing of chronic pain patients undergoing opioid therapy. Despite the potential health and financial benefits of testing for employees and employers, there is no prior study to date regarding compliance with these state policies or second-order effects.
The new report, “State Drug Testing Laws for Opioid Therapy: Implications for Employment-Based Health Plans,” uses claims data to quantify the impact of the state laws on testing rates of opioid therapy patients and document selection into treatment effects. This research provides key insights for plan sponsors and employers considering cost-effective health benefits designs to support employees with chronic pain.
“The cumulative findings indicate that the state laws have increased testing rates, and the groups with the largest increases in testing rates are those who are most likely to require opioid therapy to treat their chronic pain, showing that urine drug tests are an important diagnostic tool for doctors seeking to responsibly treat employees most in need,” said Eden Volkov, research associate, Health Benefits Research, EBRI.
Key findings in the research report include:
• Pain diagnosis rates among group plan enrollees have been relatively flat over time. Eighteen percent of enrollees were diagnosed with chronic pain in 2013, while 16% were in 2021
• Prescribing opioids for 3-plus months to chronic pain patients has been less common over time, falling from 10-12% prescribed opioids in 2013 to 1-3% in 2021.
• State drug testing laws have no impact on opioid prescribing rates.
• State drug testing laws increase testing rates among chronic pain patients prescribed opioids by 4.7 percentage points (11%).
• Effects are largest for enrollees most affected by chronic pain and in need of long-term opioid therapy, such as workers over 45 years old and those working in physically demanding jobs like construction and durable goods manufacturing.
• Mandatory testing makes healthier patients more likely to receive a pain diagnosis but has negligible effects on those who ultimately undergo opioid treatment once diagnosed.
This research report was authored by Eden Volkov, Ph.D., research associate, EBRI, Aaron M. Gamino, Ph.D., Middle Tennessee State University and Paul Fronstin, Ph.D., director, Health Benefits Research, EBRI.
“Our research findings are novel in that it is the first documented evidence of state-level policies’ efficacy in increasing testing of chronic pain patients. This evidence of the first-order effects of the state-level urine drug testing can be used to further research into the health and employment effects of urine drug testing. This report also shows drug testing doesn’t encourage overprescribing to younger and more vulnerable patients, an important risk to consider. Taken together, these results are promising and indicate that urine drug testing can be an important and powerful tool for allowing employees with pain diagnoses to receive appropriate care while remaining safe,” said Volkov.
National Opioid and Substance Awareness Day, observed on September 21, 2023, is meant to raise awareness of overdoses, reduce the stigma of drug-related deaths and acknowledge the grief felt by families and friends.
To view the complete research report, “State Drug Testing Laws for Opioid Therapy: Implications for Employment-Based Health Plans, visit www.ebri.org/opioid-testing.
The Employee Benefit Research Institute is a non-profit, independent and unbiased resource organization that provides the most authoritative and objective information about critical issues relating employee benefit programs in the United States. For more information, visit www.ebri.org.
• State drug testing lN aw EW s in S F crR ea Os M e t T es Hti E n Eg M ra PL tes OY am EE B on Eg N c Eh Fr Io T R nic E p SE aAR in p CH ati Ien NStT sI p TUT resE c ribed opioids by 4.7 percentage points (11%). New Research Finds That States’ Efforts to Increase Drug Testing of Chronic Pain Patients • Effects are largest Unde for en rr go oliln ee gs L m on og s-tT aff erm ecO ted pi b oiy d c T h he ror n aic py p H aia nv a en B de ie nn n S ee uc dc o ef ss lo fu nlg -term opioid therapy, such as workers over 45 years old and thos e working in physically demanding jobs like construction - a St n u dd d y u rr el aea ble g se o co od in sc m ides an u w fa itc ht u Nra in tig o.n al Opioid and Substance Awareness Day - F • M or ia m nm dae td oira yt t e es rel tiea ngs m e:a 9 k/ es 21 h /ea 23l thier patients more likely to receive a pain diagnosis but has n Fo eg r m ligo ib rle e eff info ec rm tsa o tin o t nh : R oo se w n Dh res o n ue lti rm ately undergo opioid treatment once diagnosed. dresner@ebri.org Th is research report was authored by Eden Volkov, Ph.D., research associate, EBRI, Aaron M. Gamino, ( Ph W.a D s.h , M ing id to dn le , D Te .C. nn ) es – A see ne S w ta rtes e U ea nric vh er rsep ityo a rt n p d P ub alu islh F e rd o t no sti dn a, y P , o hn .D N .,a d ti ir oec na tlo O r, H pio ea id lt a hn B den Su eb fisttsa R nes ce earch, E AB w R aIr . eness Day, by the Employee Benefit Research Institute (EBRI) finds that states’ efforts to increase drug testing of chronic pain patients undergoing long-term opioid therapy have been “ su Oc u cres res sfu ea l at rc i hn fi cn rea din sig n sg ar tes e n tio nv ge rla it n es th . a It n g it e isn t er he fi al, irn st c r d ea oc su em d t en es tti ed ng ev isi d im en pc o e o rtafn s tt t ao te p -r level even p t o olp iciio es id’ a eb ffic usa e a cy i nn d h ine clrp ea ps aiin ng p ta es titi en ng ts o a fn cd h t ro hn eiic r p ph ay in s p icia ati nen s sta sf.el Ty h m is ev ania dg ee t nch e o eir f c th oe fi ndir ti so t-n osr.d er effects of the s tate-level urine drug testing can be used to further research into the health and employment effects o Af s u orfi 2 ne 02 d3 r, u 2 g4 t s es ta titn es g. T ha hv is e p rep aso sr etd a lla sw o s s t hh oa w ts r d eq ru ug ir t e es pti hn ys gi c d io an es s t no ’t e per ncfo ou rm ra g u e o rinv eer dp ru res g t ces rib tiin ng g o to f y ch or u o nn gier c pa an in d m pao tir en e v ts u lu nn er da eb rg le oip na gti o en pit o si,d an th ier ma p p o yr.t D an es t r piis te t k to h c e o pn os tien deti r.a T l h ak ea en lt th o a get nd h fi er n , t an hc es iae r l bes enu elfi ts t s a or fe p tesrti on m gi f so in rg e a m np dl o in yd ee ics a an te t d h em at u p rlio ny eer ds r,u tg h t er es e i tin s g n c oa p nr b ioe r a st nu id m yp to or d ta an te t an reg da p rd oiw ng e c rfo um l tp olo ia l f no cr e al wlio th w ing t em hes pe s loytee ate p s wo itlh ic ip es ai o n rd s ia ec gn oo ns des -o t rd oer rec eff eiec ve ts a.p propriate care while remaining safe,” said Volkov. T Nh ae tio nn ew al O rep pio or id t, a “n Sd ta S te D ubsrtu ag n T ce e sA tiw na g rL ea n w es s f s D ora O y,p o io bisd er Tv h ed er o ap n y S : I ep mt p em lica bti er o 2 ns1 f,o 2 r0 E 2m 3,p ils o m ym ea en nt t -t B oa r sa ed ise a Hea walrte hn P es la sn o s, f” o u vs erd es c ols aes im , r s d ed au ta c t e t oh q e s uati ng tim fya t o he f d im rup ga -r ce t o lat f e td h e dea sta tt h e l s a an wd s ac onk t nes ow til n eg d r ga e t teh s o e g f o rip ef io fiel d t by f ta hm eria lip es y a pn ati d f en rit e sn a dn sd . d ocument selection into treatment effects. This research provides key insights for plan sponsors and employers considering cost-effective health benefits designs to support T em o v pil ew oyee ths e w co itm h c ph let ro e nr ic es p ea air nc .h report, “State Drug Testing Laws for Opioid Therapy: Implications for E mployment-Based Health Plans, visit www.ebri.org/opioid-testing. “The cumulative findings indicate that the state laws have increased testing rates, and the groups w Th it e hE tm he l plo ay rg ee es B t i en nce rfi ea t s Res es i ea n t rc es hti In ns gti rta u tt es e i a sr a e t nh oo ns -e w profi ht o, a in rd e m epe on st d len ike tl a y t no d u req nb u ia irs e o edp rie osiea d tr h cer h apy to t orr e ga atn tih za eti iro c nh t rh oa nti cp p ro av in id , s es h o th w e m ing o ts hta a t u utrh in oe ri d ta rti uv ge a tes n td s a or b e a jecn ti iv m e i pn ofro ta rm nta d tiio an g a no bs o ti u ct t c o ro iti l f co alr id ss ou ces to rs r sel ee ak ti in ng g t to o r ees mp po lo ny see ibl y b en tree afi t e t p m ro pg lo ra ym ees s i m n t o h se U t inn n it ee ed d S ,”t a sa tes id .E F d o en r m Vo orle ko in v, fo res rm ea ati rc oh n ,a v ss iso it c iate, Health B wen ww efi .eb ts rR i.es orea g. rch, EBRI. Key findings in the research report include: # # • P (M ain e di dia a g N n o o te si: T s ro at r es ec am eivo e t ng he g c ro ou mp p p ll e atn e e 1n 8r -o pa llee ges r h ea se ve arb cee h rn e r po elr atti o vr el a yl fl l a actc o ev ss er to ti m the. e E E B ig Rh I r tee ese na rch percent of enrollees were diagnoda sed ta w ba itse h c , e hr ma oniilc dr pa eis nne inr 2 @ 0e 1br 3,i w .oh rg il). e 16% were in 2021. • Prescribing opioids for 3-plus months to chronic pain patients has been less common over time, falling from 10-12% prescribed opioids in 2013 to 1-3% in 2021. • State drug testing laws have no impact on opioid prescribing rates.